Product Description
Mechanisms of Action: nAChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Polyneuropathies|Peripheral Nervous System Diseases|Neuralgia|Attention Deficit Disorder with Hyperactivity|Neuropathic Pain
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12616001318471p |
18-1100.cc | N/A |
Not yet recruiting |
Chronic Pain|Musculoskeletal Pain |
2017-10-02 |
|||
ACTRN12616001319460p |
2006-7041-83/hah | N/A |
Not yet recruiting |
Cataract|Vision Disorders |
None |
|||
2007-001140-47 |
2007-001140-47 | P2 |
Completed |
Neuropathic Pain |
2008-12-02 |
2025-06-26 |
Treatments |
|
NCT00548925 |
M10-014 | P2 |
Completed |
Neuralgia|Neuropathic Pain |
2008-12-01 |
2019-03-22 |
Treatments |
|
2007-001139-71 |
2007-001139-71 | P2 |
Completed |
Neuropathic Pain |
2008-10-07 |
2022-03-12 |
Treatments |
|
NCT00507936 |
M06-850 | P2 |
Completed |
Peripheral Nervous System Diseases|Neuralgia|Polyneuropathies |
2008-10-01 |
2019-03-21 |
Treatments |
|
NCT00429091 |
M06-818 | P2 |
Completed |
Attention Deficit Disorder with Hyperactivity |
2007-08-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/29/2021 |
PubMed |
Different Drugs for the Treatment of Painful Diabetic Peripheral Neuropathy: A Meta-Analysis. |
|
10/01/2021 |
PubMed |
Bicyclic Pyrrolidines for Medicinal Chemistry via [3 + 2]-Cycloaddition. |